Alteogen Signs $365M Global Deal for Hybrozyme Platform
Daejeon, South Korea, August 5, 2026 Alteogen Inc. has entered into an exclusive license agreement with an undisclosed global...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Daejeon, South Korea, August 5, 2026 Alteogen Inc. has entered into an exclusive license agreement with an undisclosed global...
SAN DIEGO and MENLO PARK, Calif., May 6, 2026 Halozyme Therapeutics and Oruka Therapeutics announced a global exclusive collaboration...
Cambridge, UK, 30 October 2025 – Alexion, AstraZeneca Rare Disease, today announced positive results from the global Phase III...
